These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 18801072)
1. Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia. Peh SC; Gan GG; Lee LK; Eow GI Pathol Int; 2008 Sep; 58(9):572-9. PubMed ID: 18801072 [TBL] [Abstract][Full Text] [Related]
2. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry]. Ye ZY; Cao YB; Lin TY; Lin HL Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597 [TBL] [Abstract][Full Text] [Related]
3. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification. Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival. Dwivedi A; Mehta A; Solanki P Indian J Pathol Microbiol; 2015; 58(4):453-8. PubMed ID: 26549066 [TBL] [Abstract][Full Text] [Related]
5. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis]. Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis. Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707 [TBL] [Abstract][Full Text] [Related]
7. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases]. Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994 [TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530 [TBL] [Abstract][Full Text] [Related]
9. p63 protein expression in high risk diffuse large B-cell lymphoma. Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865 [TBL] [Abstract][Full Text] [Related]
10. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma]. Yao XX; Wang JF; Wang YH; Gao N Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402 [TBL] [Abstract][Full Text] [Related]
11. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation. Song Y; Cao Z; Li L; Zhang HT; Zhang X Chin J Cancer; 2010 Sep; 29(9):781-6. PubMed ID: 20800019 [TBL] [Abstract][Full Text] [Related]
12. [State of chromosome 3q27 and different subtypes of diffuse large B-cell lymphoma and their prognostic correlation]. Li Y; Wang GP; Xi YF; Wang JF; Bai W Zhonghua Bing Li Xue Za Zhi; 2009 Apr; 38(4):231-6. PubMed ID: 19575893 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic evaluation of subgroups of diffuse large B cell lymphoma by immunohistochemistry. Naz E; Mirza T; Danish F Asian Pac J Cancer Prev; 2011; 12(12):3335-9. PubMed ID: 22471476 [TBL] [Abstract][Full Text] [Related]
15. The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas. Rayman N; Lam KH; van der Holt B; Koss C; van Leeuwen J; Budel LM; Mulder AH; Sonneveld P; Delwel R Eur J Haematol; 2011 Jun; 86(6):466-76. PubMed ID: 21457344 [TBL] [Abstract][Full Text] [Related]
16. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. De Paepe P; Achten R; Verhoef G; Wlodarska I; Stul M; Vanhentenrijk V; Praet M; De Wolf-Peeters C J Clin Oncol; 2005 Oct; 23(28):7060-8. PubMed ID: 16129841 [TBL] [Abstract][Full Text] [Related]
17. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma. Hallack Neto AE; Siqueira SA; Dulley FL; Chauobah A; Belesso M; Saboia R; Ruiz MA; Chamone DA; Pereira J Sao Paulo Med J; 2010 Jan; 128(1):14-7. PubMed ID: 20512275 [TBL] [Abstract][Full Text] [Related]
18. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904 [TBL] [Abstract][Full Text] [Related]
19. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. Anderson JJ; Fordham S; Overman L; Dignum H; Wood K; Proctor SJ; Crosier S; Angus B; Culpin RE; Mainou-Fowler T Int J Oncol; 2009 Nov; 35(5):961-71. PubMed ID: 19787248 [TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma]. Li M; Liu CL; Wang XY; Xue XM; Gao ZF Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]